4 results on '"A. Sartani"'
Search Results
2. Localization of nonpalpable breast lesions with sonographically visible clip: optimizing tailored resection and clear margins.
- Author
-
Corsi, Fabio, Sorrentino, Luca, Sartani, Alessandra, Bossi, Daniela, Amadori, Rosella, Nebuloni, Manuela, Truffi, Marta, Bonzini, Matteo, and Foschi, Diego
- Subjects
- *
BREAST , *SURGICAL excision , *ULTRASONIC imaging , *LUMPECTOMY , *PREOPERATIVE care , *BREAST biopsy , *WOUNDS & injuries - Abstract
BACKGROUND: Achieving clear margins with adequate resection volumes is one of the principal goals of breast-conserving surgery. The aim of our study was to compare preoperative localization using 2 different clips, radiopaque or sonographically visible, to reach this goal. METHODS: We reviewed 209 consecutive nonpalpable breast cancers that were treated with lumpectomy: 59 with radiopaque and 150 with sonographically visible clip positioned during biopsy procedure. In the former case, preoperative localization was performed with mammography and in the latter by ultrasonography. RESULTS: Clear margins were achieved in 80.4% of patients: 57.6% in the first and 89.3% in the second group (P < .0001; odds ratio, 7.6; 95% confidence interval, 3.4 to 17.2). By using sonographically visible clips, the re-excision rate has decreased from 42.4% to 10.7%, (P < .0001), and resections resulted smaller with average calculated resection ratio of 3.54 vs 5.08 (P = .03). CONCLUSIONS: Preoperative localization using a sonographically visible clip allows a more tailored breast-conserving surgery and reduces the re-excision rate. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
3. Treatment of Dry Eye Syndrome with Orally Administered CF101: Data from a Phase 2 Clinical Trial
- Author
-
Avni, Isaac, Garzozi, Hanna J., Barequet, Irina S., Segev, Fanni, Varssano, David, Sartani, Gil, Chetrit, Noa, Bakshi, Erez, Zadok, David, Tomkins, Oren, Litvin, Gilad, Jacobson, Kenneth A., Fishman, Sari, Harpaz, Zivit, Farbstein, Motti, Yehuda, Sara Bar, Silverman, Michael H., Kerns, William D., Bristol, David R., and Cohn, Ilan
- Subjects
- *
ORAL drug administration , *DRUG administration , *MEDICAL statistics , *MEDICATION safety , *DRUG efficacy , *CLINICAL trials , *ADENOSINES ,TREATMENT of dry eye syndromes - Abstract
Objective: To explore the safety and efficacy of CF101, an A3 adenosine receptor agonist, in patients with moderate to severe dry eye syndrome. Design: Phase 2, multicenter, randomized, double-masked, placebo-controlled, parallel-group study. Participants: Sixty-eight patients completed the study, 35 patients in the placebo group and 33 patients in the CF101 group. Intervention: Patients were treated orally with either 1 mg CF101 pills or matching vehicle-filled placebo pills, given twice daily for 12 weeks, followed by a 2-week posttreatment observation. Main Outcome Measures: An improvement of more than 25% over baseline at week 12 in one of the following parameters: (1) tear break-up time (BUT); (2) superficial punctate keratitis assessed by fluorescein staining results; and (3) Schirmer tear test 1 results. Clinical laboratory safety tests, ophthalmic examinations, intraocular pressure (IOP) measurements, electrocardiographic evaluations, vital sign measurements, and monitoring of adverse events. Results: A statistically significant increase in the proportion of patients who achieved more than 25% improvement in the corneal staining and in the clearance of corneal staining was noted between the CF101-treated group and the placebo group. Treatment with CF101 resulted in a statistically significant improvement in the mean change from baseline at week 12 of the corneal staining, BUT, and tear meniscus (TM) height in the CF101-treated group. CF101 was well tolerated and exhibited an excellent safety profile with no serious adverse events. A statistically significant decrease from baseline was observed in the IOP of the CF101-treated group in comparison with the placebo group. Conclusions: CF101, given orally, induced a statistically significant improvement in the corneal staining and an improvement in the BUT and TM in patients with moderate to severe dry eye syndrome. The drug was very well tolerated. These data and the anti-inflammatory characteristic of CF101 support further study of the drug as a potential treatment for the signs and symptoms of dry eye syndrome. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
4. A prospective, longitudinal study of nonconventional strictureplasty in Crohn’rsquo;s disease
- Author
-
Sampietro, Gianluca M, Cristaldi, Massimo, Maconi, Giovanni, Parente, Fabrizio, Sartani, Alessandra, Ardizzone, Sandro, Danelli, Piergiorgio, Porro, Gabriele Bianchi, and Taschieri, Angelo Maria
- Subjects
- *
OPERATIVE surgery , *SURGICAL excision , *CROHN'S disease , *MORTALITY - Abstract
Background: Bowel-sparing techniques have been proposed to avoid extended or repeated resections in patients with Crohn’rsquo;s disease (CD), but without precise indications, prospective evaluation, and with a technically limited repertoire.Study design: A prospective longitudinal study of new nonconventional strictureplasties (NCSP) in order to evaluate the safety, type and site of recurrence, and longterm clinical and surgical efficacy.Results: Between January 1993 and December 2002, 102 among 305 consecutive patients underwent at least one NCSP for complicated CD. Patients were treated following precise indications and then included in a prospective database with scheduled followup. Factors claimed to influence postoperative and longterm outcomes and type and site of recurrence were analyzed. We performed 48 ileoileal side-to-side isoperistaltic strictureplasty (SP), 41 widening ileocolic SP, 32 ileocolic side-to-side isoperistaltic SP, associated with Heineke-Mikulicz SP (in 80 procedures) or with minimal bowel resections or both (in 47 procedures). Postoperative mortality was nil; complication rate was 5.7%. Ten years clinical and surgical recurrence rates were 43% and 27%, respectively. Recurrence rate on an NCSP site was 0.8%. No specific factor was identified as related to postoperative or longterm outcomes.Conclusions: Perioperative and longterm results of NCSP are comparable to or even better than both conservative and resective surgery as reported in the literature, with a low recurrence rate on the NCSP site. Considering the unpredictability of the clinical course of CD and the lifetime need for surgical procedures, NCSP, together with minimal resection and classic SP repertoire, should be considered first-line treatment in complicated CD. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.